Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases

Rachel A. Freedman, Rebecca S. Gelman, Jeffrey S. Wefel, Michelle E. Melisko, Kenneth R. Hess, Roisin M. Connolly, Catherine H. Van Poznak, Polly A. Niravath, Shannon L. Puhalla, Nuhad Ibrahim, Kimberly L. Blackwell, Beverly Moy, Christina Herold, Minetta C. Liu, Alarice Lowe, Nathalie Y.R. Agar, Nicole Ryabin, Sarah Farooq, Elizabeth Lawler, Mothaffar F. RimawiIan E. Krop, Antonio C. Wolff, Eric P. Winer, Nancy U. Lin

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Fingerprint

Dive into the research topics of 'Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences